Regularly monitor complete blood counts (CBCs), including platelet counts, particularly during prolonged therapy. Pay close attention to any signs of myelosuppression, such as fatigue, bruising, or bleeding. Report significant drops in any blood cell counts immediately.
Assess patients for signs of peripheral neuropathy, such as numbness, tingling, or pain in the extremities. Encourage patients to report any new or worsening neurological symptoms. Consider discontinuing Linezolid if neuropathy develops.
Monitor serum creatinine and BUN levels to detect potential renal impairment. Adjust dosage as necessary based on renal function. Hydration can help mitigate renal side effects.
Carefully observe patients for signs of lactic acidosis, including nausea, vomiting, abdominal pain, and increased respiratory rate. Promptly measure blood lactate levels if symptoms arise. Discontinue Linezolid if lactic acidosis is confirmed.
Closely watch for signs of serotonin syndrome, such as agitation, confusion, and hyperreflexia, especially when Linezolid is used concomitantly with serotonergic drugs. Immediately stop Linezolid and manage symptoms if serotonin syndrome develops.
Assess for optic neuritis, characterized by vision changes, including blurred vision or decreased visual acuity. Prompt ophthalmological evaluation is warranted if visual problems occur. Linezolid discontinuation may be necessary.
Inform patients about potential side effects and encourage them to report any unusual symptoms. Regular follow-up appointments are crucial for effective monitoring and management of potential adverse events.
